{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Sandra Spalek",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Discriminative Stimulus Properties of S(−)-Nicotine: “A Drug for All Seasons",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "PUBCHEM": "^\\d+$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mesh-names.belns"
    },
    "path": "anatabine/rosecrans2017.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Adrenal Glands": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "For example, immediately after exposure to nicotine, there is a “stimulant-kick” caused, in part, by its stimulation of the adrenal glands and resultant discharge of epinephrine (adrenaline)",
      "key": "9f4e474c38e6e95105845931787b247c",
      "line": 79,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 14,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Adrenal Glands": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "For example, immediately after exposure to nicotine, there is a “stimulant-kick” caused, in part, by its stimulation of the adrenal glands and resultant discharge of epinephrine (adrenaline)",
      "key": "7f94ebdff9374f4d99ebc80a41b43998",
      "line": 80,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 14,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Pancreas": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Nicotine also suppresses insulin output from the pancreas, which indicates that smokers are usually hyperglycemic (higher blood sugar level)",
      "key": "944664421ef4166fa3b2fa59487478f7",
      "line": 96,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "decreases",
      "source": 14,
      "target": 5
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Centrally, (-)-nicotine has affinity for all brain nAChR subtypes, but binds preferentially and with high affinity to α4β2 nAChRs (e.g., [12, 13])",
      "key": "f086e4af12eb91226bb4fd6e7fec71b6",
      "line": 105,
      "relation": "association",
      "source": 14,
      "target": 43
    },
    {
      "key": "56d83c1c85088922aab456fe88c1cbf6",
      "relation": "partOf",
      "source": 14,
      "target": 40
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Centrally, (-)-nicotine has affinity for all brain nAChR subtypes, but binds preferentially and with high affinity to α4β2 nAChRs (e.g., [12, 13])",
      "key": "373b7d973c1b454f162e1589490a774a",
      "line": 106,
      "relation": "increases",
      "source": 14,
      "target": 40
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "(-)-Nicotine activates all brain nAChR subtypes, but binds preferentially and with high affinity to α4β2 nAChRs (e.g., [12])",
      "key": "f7a39357d9766dd15b730abc47a0669e",
      "line": 191,
      "relation": "increases",
      "source": 14,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Moreover, (-)-nicotine (indirectly) can produce a release of dopamine in brain regions that are thought to control pleasure and motivation; dopamine is thought to underlie the pleasurable sensations experienced by smokers (e.g., [14, 15] but see [16]).",
      "key": "6be187733ee80247e4e4b7eac711cb72",
      "line": 115,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 14,
      "target": 11
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Nucleus Accumbens": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "For example, (-)-nicotine may increase dopamine activity at some brain sites such as the nucleus accumbens, an area thought to be important to drugs of abuse (e.g., [14, 101, 102]; but see [16, 103])",
      "key": "77dc4cc331f15ae62cca479d978a66cc",
      "line": 200,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 14,
      "target": 11
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9989": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "For example, in rodents, administration of low doses of nicotine produced increased motor activity whereas high doses produced decreased motor activity (e.g.,[17, 18])",
      "key": "c44e142ad126dbb0f3d0cca000b7924c",
      "line": 127,
      "relation": "negativeCorrelation",
      "source": 14,
      "target": 51
    },
    {
      "key": "995315c886108b2c25bffee21b67c639",
      "relation": "partOf",
      "source": 14,
      "target": 30
    },
    {
      "key": "021650bf0caf43b307d532629af8f371",
      "relation": "partOf",
      "source": 14,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": ". It is now well established that nicotine binds to nicotinic acetylcholine receptors (nAChRs) at the cellular level and is the prototype drug used to classify nAChRs",
      "key": "7f6f5b0600656a0fe73cee51084bbdb1",
      "line": 183,
      "relation": "increases",
      "source": 14,
      "target": 39
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "(-)-Nicotine activates all brain nAChR subtypes, but binds preferentially and with high affinity to α4β2 nAChRs (e.g., [12])",
      "key": "f89d0ad7b6618b6c5a99a779513f80f9",
      "line": 190,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 14,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "In antagonism tests, (-)-nicotine failed to block the stimulus effects of mecamylamine",
      "key": "a0bacab3107086e4bf380e99196ae6c5",
      "line": 312,
      "object": {
        "modifier": "Activity"
      },
      "relation": "causesNoChange",
      "source": 14,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": ". It should be noted that hexamethonium, at relatively low doses, does not block the stimulus effects of (-)-nicotine but when administered at high doses has occasionally been reported to attenuate nicotine-like responding; probably the result of penetration into the CNS of a small proportion of the administered dose of drug (e.g., [35, 38, 64, 106, 146])",
      "key": "0b571e859ae0386a31740ca9effa7495",
      "line": 323,
      "relation": "negativeCorrelation",
      "source": 14,
      "subject": {
        "modifier": "Activity"
      },
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Adrenal Glands": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "The release of epinephrine stimulates the body and causes a sudden release of glucose as well as an increase in blood pressure, respiration, and heart rate",
      "key": "51d45c1ada60a83c21874085a4b8dddc",
      "line": 86,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 9,
      "subject": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Adrenal Glands": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "The release of epinephrine stimulates the body and causes a sudden release of glucose as well as an increase in blood pressure, respiration, and heart rate",
      "key": "c2fb723e9d62bba3b186bf986994a380",
      "line": 87,
      "relation": "increases",
      "source": 9,
      "subject": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Adrenal Glands": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "The release of epinephrine stimulates the body and causes a sudden release of glucose as well as an increase in blood pressure, respiration, and heart rate",
      "key": "894497846c18840e3f53f40fddba2704",
      "line": 88,
      "relation": "increases",
      "source": 9,
      "subject": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Adrenal Glands": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "The release of epinephrine stimulates the body and causes a sudden release of glucose as well as an increase in blood pressure, respiration, and heart rate",
      "key": "a40cf1e73c51476a3fad022d341df77d",
      "line": 89,
      "relation": "increases",
      "source": 9,
      "subject": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Nicotine also suppresses insulin output from the pancreas, which indicates that smokers are usually hyperglycemic (higher blood sugar level)",
      "key": "10b46cd240076c9ac76e6352e3e92d90",
      "line": 98,
      "relation": "increases",
      "source": 67,
      "target": 19
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Centrally, (-)-nicotine has affinity for all brain nAChR subtypes, but binds preferentially and with high affinity to α4β2 nAChRs (e.g., [12, 13])",
      "key": "bb689347577c6d5682a640ba88b79b28",
      "line": 105,
      "relation": "association",
      "source": 43,
      "target": 14
    },
    {
      "key": "26773a5f3ca0c4a1302a06b74befc98d",
      "relation": "partOf",
      "source": 44,
      "target": 43
    },
    {
      "key": "6fc3fbf017e49ed1986855d7f0d9a4c9",
      "relation": "partOf",
      "source": 27,
      "target": 40
    },
    {
      "key": "d9561d658c147416cbdff9bd6d974126",
      "relation": "partOf",
      "source": 27,
      "target": 41
    },
    {
      "key": "939ca8605b3f98034f79d216151d6006",
      "relation": "partOf",
      "source": 27,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Moreover, (-)-nicotine (indirectly) can produce a release of dopamine in brain regions that are thought to control pleasure and motivation; dopamine is thought to underlie the pleasurable sensations experienced by smokers (e.g., [14, 15] but see [16]).",
      "key": "e2f0fa3ffbbc0cd811999272d537c634",
      "line": 116,
      "relation": "regulates",
      "source": 11,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Moreover, (-)-nicotine (indirectly) can produce a release of dopamine in brain regions that are thought to control pleasure and motivation; dopamine is thought to underlie the pleasurable sensations experienced by smokers (e.g., [14, 15] but see [16]).",
      "key": "34219550f214dd6cee82b0da3df016aa",
      "line": 117,
      "relation": "regulates",
      "source": 11,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9989": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "For example, in rodents, administration of low doses of nicotine produced increased motor activity whereas high doses produced decreased motor activity (e.g.,[17, 18])",
      "key": "05782cfac46f3df939656c15059f924d",
      "line": 127,
      "relation": "negativeCorrelation",
      "source": 51,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "In comparison, S(-)-nicotine was shown to be 7 times more toxic than R(+)-nicotine in rats injected intravenously",
      "key": "897e2c9d6e2cb3df5a841f3313ca2d3e",
      "line": 136,
      "relation": "increases",
      "source": 4,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "In comparison, S(-)-nicotine was shown to be 7 times more toxic than R(+)-nicotine in rats injected intravenously",
      "key": "0502cf6cbbd55c73df4f5635bee53546",
      "line": 138,
      "relation": "increases",
      "source": 4,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "In comparison, S(-)-nicotine was shown to be 7 times more toxic than R(+)-nicotine in rats injected intravenously",
      "key": "9689b6d8c5ce32b80db0a68528baf30b",
      "line": 137,
      "relation": "increases",
      "source": 2,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "In comparison, S(-)-nicotine was shown to be 7 times more toxic than R(+)-nicotine in rats injected intravenously",
      "key": "60d2f54f49832dfd2ce885568c6a9228",
      "line": 139,
      "relation": "increases",
      "source": 2,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Lastly, S(-)-nornicotine is a minor metabolite of nicotine and, as mentioned previously, is considered a minor alkaloid of tobacco (Fig. 2)",
      "key": "3e746f585ebedadff9f41f35294663c5",
      "line": 176,
      "relation": "isA",
      "source": 30,
      "target": 15
    },
    {
      "key": "404aa30bb5e575484674ec05021dc2db",
      "relation": "partOf",
      "source": 6,
      "target": 30
    },
    {
      "key": "0561d7fc8b6a4a21a1b54fe5a0d40bfc",
      "relation": "partOf",
      "source": 15,
      "target": 30
    },
    {
      "key": "ad633c7e7aa4c8017c8f1b4b1133c4f2",
      "relation": "partOf",
      "source": 3,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "In the body, nicotine is extensively metabolized and is susceptible to a significant first-pass effect during which 80–90% of it is metabolized by the liver. Also, the lung is able to metabolize nicotine, but to a much lesser degree [78, 79]. ",
      "key": "1659c92f517f051c25a97f25ff89593b",
      "line": 157,
      "relation": "increases",
      "source": 28,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": " In humans, about 70–80% of nicotine is converted to the primary metabolite (-)-cotinine, a lactam derivative (Fig. 2).",
      "key": "50e344901cc99878f285b670f273d4f4",
      "line": 166,
      "relation": "increases",
      "source": 35,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Lastly, S(-)-nornicotine is a minor metabolite of nicotine and, as mentioned previously, is considered a minor alkaloid of tobacco (Fig. 2)",
      "key": "cd212db8b304dd91dc381e8cda3b9f97",
      "line": 175,
      "relation": "increases",
      "source": 35,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "In the body, nicotine is extensively metabolized and is susceptible to a significant first-pass effect during which 80–90% of it is metabolized by the liver. Also, the lung is able to metabolize nicotine, but to a much lesser degree [78, 79]. ",
      "key": "2f9b6684cbfab69e95fbec4ccb49adf2",
      "line": 158,
      "relation": "increases",
      "source": 29,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": " In humans, about 70–80% of nicotine is converted to the primary metabolite (-)-cotinine, a lactam derivative (Fig. 2).",
      "key": "61c0dc08f652bfca35716390fa2031d3",
      "line": 165,
      "relation": "isA",
      "source": 0,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": " In humans, about 70–80% of nicotine is converted to the primary metabolite (-)-cotinine, a lactam derivative (Fig. 2).",
      "key": "7c490df4989327a9d4c19f8c785bfd38",
      "line": 167,
      "relation": "association",
      "source": 0,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": " In humans, about 70–80% of nicotine is converted to the primary metabolite (-)-cotinine, a lactam derivative (Fig. 2).",
      "key": "9f08d5eaedd4fe2880d365b30a4780a6",
      "line": 167,
      "relation": "association",
      "source": 13,
      "target": 0
    },
    {
      "key": "a3ce0f311aec532ea5bf04e898034c53",
      "relation": "partOf",
      "source": 17,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "This conclusion is based on the fact that the stimulus effects of nicotine are convincingly blocked by (a) mecamylamine, a voltage dependent noncompetitive channel blocker at nicotinic receptors (Fig. 3; Table 4) and (b) dihydro-β-erythrodine (DHβE), a nicotinic receptor antagonist that shows high affinity for the nAChR α4β2 subunit (Fig. 3; Table 5) but not by methyllycaconitine (MLA), a α7 nicotinic receptor antagonist (Table 5).",
      "key": "355fe59a993ca69240cc6741289ba2b3",
      "line": 211,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 8,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "This conclusion is based on the fact that the stimulus effects of nicotine are convincingly blocked by (a) mecamylamine, a voltage dependent noncompetitive channel blocker at nicotinic receptors (Fig. 3; Table 4) and (b) dihydro-β-erythrodine (DHβE), a nicotinic receptor antagonist that shows high affinity for the nAChR α4β2 subunit (Fig. 3; Table 5) but not by methyllycaconitine (MLA), a α7 nicotinic receptor antagonist (Table 5).",
      "key": "29c2602c32ce4d3c8c5b455ff78810cd",
      "line": 212,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 8,
      "target": 22
    },
    {
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "For example, some biochemical studies suggest that mecamylamine is a channel blocker that inhibits most neuronal nAChRs (e.g., [131–133]).",
      "key": "c0e023ecbf5252e1d427f973b2d9df67",
      "line": 256,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 8,
      "target": 22
    },
    {
      "annotations": {
        "Cell": {
          "ganglion interneuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Mecamylamine (Inversine®, Vecamyl®; Fig. 3) was developed over 60 years ago and marketed as a ganglionic blocker for the treatment of hypertension (e.g., [127])",
      "key": "545c4326388e72e213525dedef599463",
      "line": 224,
      "relation": "decreases",
      "source": 8,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": " In addition, mecamylamine can produce CNS effects that include tremor, mental confusion, seizures, mania, and depression but the mechanisms by which these effects are produced are unclear",
      "key": "b870b7d4657a8a3f2616efe5669a226a",
      "line": 232,
      "relation": "increases",
      "source": 8,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": " In addition, mecamylamine can produce CNS effects that include tremor, mental confusion, seizures, mania, and depression but the mechanisms by which these effects are produced are unclear",
      "key": "2f7f36a6935c3e474ec20661b3243650",
      "line": 233,
      "relation": "increases",
      "source": 8,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": " In addition, mecamylamine can produce CNS effects that include tremor, mental confusion, seizures, mania, and depression but the mechanisms by which these effects are produced are unclear",
      "key": "0bbdb8dab3eaac235d3a25eb618b5b99",
      "line": 234,
      "relation": "increases",
      "source": 8,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": " In addition, mecamylamine can produce CNS effects that include tremor, mental confusion, seizures, mania, and depression but the mechanisms by which these effects are produced are unclear",
      "key": "1b0f4b51c4a89287f08dce9034d9c150",
      "line": 235,
      "relation": "increases",
      "source": 8,
      "target": 48
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": " In addition, mecamylamine can produce CNS effects that include tremor, mental confusion, seizures, mania, and depression but the mechanisms by which these effects are produced are unclear",
      "key": "5e21122ccc450a18fda04fcebf3f2d13",
      "line": 236,
      "relation": "increases",
      "source": 8,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Biochemical and pharmacological studies have characterized mecamylamine as a nonselective, voltage dependent and noncompetitive receptor antagonist of neuronal nAChRs and it is often referred to as a “nicotine receptor antagonist.”",
      "key": "24533f29541270766ea2e5b4c4af5a28",
      "line": 251,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 8,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "This conclusion is based on the fact that the stimulus effects of nicotine are convincingly blocked by (a) mecamylamine, a voltage dependent noncompetitive channel blocker at nicotinic receptors (Fig. 3; Table 4) and (b) dihydro-β-erythrodine (DHβE), a nicotinic receptor antagonist that shows high affinity for the nAChR α4β2 subunit (Fig. 3; Table 5) but not by methyllycaconitine (MLA), a α7 nicotinic receptor antagonist (Table 5).",
      "key": "3fec86c9e5507c52ea77494ec6d83dfd",
      "line": 213,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true,
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Research results summarized in Table 5 indicate that DHβE effectively blocked the stimulus effects of (-)-nicotine in rats or mice (but see exceptions reported by [120, 121]).",
      "key": "77a884c9623962abb5c9910403140b93",
      "line": 289,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 14
    },
    {
      "key": "687697e03c4d93bca48eb0156dd4b6bc",
      "relation": "partOf",
      "source": 21,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "This conclusion is based on the fact that the stimulus effects of nicotine are convincingly blocked by (a) mecamylamine, a voltage dependent noncompetitive channel blocker at nicotinic receptors (Fig. 3; Table 4) and (b) dihydro-β-erythrodine (DHβE), a nicotinic receptor antagonist that shows high affinity for the nAChR α4β2 subunit (Fig. 3; Table 5) but not by methyllycaconitine (MLA), a α7 nicotinic receptor antagonist (Table 5).",
      "key": "af91e99b64bcf9782bb687a3d03d7e0f",
      "line": 214,
      "relation": "increases",
      "source": 21,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "This conclusion is based on the fact that the stimulus effects of nicotine are convincingly blocked by (a) mecamylamine, a voltage dependent noncompetitive channel blocker at nicotinic receptors (Fig. 3; Table 4) and (b) dihydro-β-erythrodine (DHβE), a nicotinic receptor antagonist that shows high affinity for the nAChR α4β2 subunit (Fig. 3; Table 5) but not by methyllycaconitine (MLA), a α7 nicotinic receptor antagonist (Table 5).",
      "key": "77a99ffaa09b19f9ec4aeb0f2a002534",
      "line": 215,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "3841": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "DHβE (Fig. 3) is an alkaloid found in plant seeds of Erythrina and is a competitive nAChR receptor antagonist with a preference for neuronal β2 subtypes",
      "key": "397bb3d5e600ffc8fd990d8e4b5368c2",
      "line": 264,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 46
    },
    {
      "key": "a9956017c83775494a7456c8d3f41244",
      "relation": "partOf",
      "source": 21,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "3841": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "DHβE (Fig. 3) is an alkaloid found in plant seeds of Erythrina and is a competitive nAChR receptor antagonist with a preference for neuronal β2 subtypes",
      "key": "10e65c3c82875cdaf34878b1381c51da",
      "line": 265,
      "relation": "increases",
      "source": 21,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "For example, DHβE (at nM concentrations) blocks α4β2 and α3β2 nAChRs but is much less potent at α3β4 and α7 nAChRs expressed in Xenopus oocytes (e.g., [134–137]).",
      "key": "a6601a2ce3d61b2cf8c6efc0e74623f2",
      "line": 273,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "For example, DHβE (at nM concentrations) blocks α4β2 and α3β2 nAChRs but is much less potent at α3β4 and α7 nAChRs expressed in Xenopus oocytes (e.g., [134–137]).",
      "key": "6d2f21fbd5a184ad6d6959ceb2bfb8e8",
      "line": 274,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 27
    },
    {
      "annotations": {
        "Cell": {
          "oocyte": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "262014": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "For example, DHβE (at nM concentrations) blocks α4β2 and α3β2 nAChRs but is much less potent at α3β4 and α7 nAChRs expressed in Xenopus oocytes (e.g., [134–137]).",
      "key": "8e8b3b84318b9d457d93a5b731f0d7f6",
      "line": 277,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 26
    },
    {
      "annotations": {
        "Cell": {
          "oocyte": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "262014": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "For example, DHβE (at nM concentrations) blocks α4β2 and α3β2 nAChRs but is much less potent at α3β4 and α7 nAChRs expressed in Xenopus oocytes (e.g., [134–137]).",
      "key": "5c18b746d9bced536c672c27bd1bc548",
      "line": 278,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "This conclusion is based on the fact that the stimulus effects of nicotine are convincingly blocked by (a) mecamylamine, a voltage dependent noncompetitive channel blocker at nicotinic receptors (Fig. 3; Table 4) and (b) dihydro-β-erythrodine (DHβE), a nicotinic receptor antagonist that shows high affinity for the nAChR α4β2 subunit (Fig. 3; Table 5) but not by methyllycaconitine (MLA), a α7 nicotinic receptor antagonist (Table 5).",
      "key": "9f6489e33b3b2b22d54b31c10a5b4430",
      "line": 216,
      "object": {
        "modifier": "Activity"
      },
      "relation": "causesNoChange",
      "source": 32,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true,
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Table 5 presents results of MLA/(-)-nicotine combination studies and shows that MLA failed to alter the stimulus effects of (-)-nicotine in rats or mice (but see partial antagonism reported by Quarta et al. [126])",
      "key": "72c7e043988694b021bb1b2d9d10d104",
      "line": 306,
      "object": {
        "modifier": "Activity"
      },
      "relation": "causesNoChange",
      "source": 32,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "This conclusion is based on the fact that the stimulus effects of nicotine are convincingly blocked by (a) mecamylamine, a voltage dependent noncompetitive channel blocker at nicotinic receptors (Fig. 3; Table 4) and (b) dihydro-β-erythrodine (DHβE), a nicotinic receptor antagonist that shows high affinity for the nAChR α4β2 subunit (Fig. 3; Table 5) but not by methyllycaconitine (MLA), a α7 nicotinic receptor antagonist (Table 5).",
      "key": "75aa3f1d6722c0e6391bf0bd7d578b3d",
      "line": 217,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 32,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Its biochemical pharmacology indicates that it is a relatively potent competitive receptor antagonist that is selective for α7 nAChRs (e.g., [139–141]).",
      "key": "28a7fa8b3ac0f0c1e5a049acbb295965",
      "line": 297,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 32,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": " Also, mecamylamine is sometimes used as an anti-addictive drug to help people stop smoking tobacco products (e.g.,[128, 129])",
      "key": "01a75132a168438f326dd7beac54f636",
      "line": 243,
      "relation": "decreases",
      "source": 31,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": " Also, mecamylamine is sometimes used as an anti-addictive drug to help people stop smoking tobacco products (e.g.,[128, 129])",
      "key": "d988446bff0af38ba94e70d9eca759bf",
      "line": 244,
      "relation": "decreases",
      "source": 31,
      "target": 67
    },
    {
      "key": "c0b9e642bf74f6d44549c415842825dd",
      "relation": "hasMember",
      "source": 45,
      "target": 46
    },
    {
      "key": "88116b197887cdc5faf28ce02e97b741",
      "relation": "partOf",
      "source": 45,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": ". It should be noted that hexamethonium, at relatively low doses, does not block the stimulus effects of (-)-nicotine but when administered at high doses has occasionally been reported to attenuate nicotine-like responding; probably the result of penetration into the CNS of a small proportion of the administered dose of drug (e.g., [35, 38, 64, 106, 146])",
      "key": "cb4c48b4e9003882f16762503e89538b",
      "line": 322,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "Central Nervous System",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 7,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": ". It should be noted that hexamethonium, at relatively low doses, does not block the stimulus effects of (-)-nicotine but when administered at high doses has occasionally been reported to attenuate nicotine-like responding; probably the result of penetration into the CNS of a small proportion of the administered dose of drug (e.g., [35, 38, 64, 106, 146])",
      "key": "1a81f74a68b506cff0ceb55c961d6cd1",
      "line": 323,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 7,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "(-)-Nicotine withdrawal symptoms might begin within a few hours after the last nicotine product, and include irritability/anger/stress/anxiety, sleep disturbances, depressed mood, craving, cognitive and attention deficits, and increased appetite.",
      "key": "067111dea5faf3b64295b5ebc6a336f1",
      "line": 330,
      "relation": "increases",
      "source": 53,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "(-)-Nicotine withdrawal symptoms might begin within a few hours after the last nicotine product, and include irritability/anger/stress/anxiety, sleep disturbances, depressed mood, craving, cognitive and attention deficits, and increased appetite.",
      "key": "649f529ac3e577d884c5d1356263b8dc",
      "line": 331,
      "relation": "increases",
      "source": 53,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "(-)-Nicotine withdrawal symptoms might begin within a few hours after the last nicotine product, and include irritability/anger/stress/anxiety, sleep disturbances, depressed mood, craving, cognitive and attention deficits, and increased appetite.",
      "key": "c4154e6edd92d1df3e437f0e78f6634e",
      "line": 332,
      "relation": "increases",
      "source": 53,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "(-)-Nicotine withdrawal symptoms might begin within a few hours after the last nicotine product, and include irritability/anger/stress/anxiety, sleep disturbances, depressed mood, craving, cognitive and attention deficits, and increased appetite.",
      "key": "d1a5364864c9ea1002125111ca05e372",
      "line": 333,
      "relation": "increases",
      "source": 53,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "(-)-Nicotine withdrawal symptoms might begin within a few hours after the last nicotine product, and include irritability/anger/stress/anxiety, sleep disturbances, depressed mood, craving, cognitive and attention deficits, and increased appetite.",
      "key": "33770e0b81f10c2bdd43dd56af47159b",
      "line": 334,
      "relation": "increases",
      "source": 53,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "(-)-Nicotine withdrawal symptoms might begin within a few hours after the last nicotine product, and include irritability/anger/stress/anxiety, sleep disturbances, depressed mood, craving, cognitive and attention deficits, and increased appetite.",
      "key": "0408e8d414bb13e7f45bfec3f7dbe552",
      "line": 335,
      "relation": "increases",
      "source": 53,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "(-)-Nicotine withdrawal symptoms might begin within a few hours after the last nicotine product, and include irritability/anger/stress/anxiety, sleep disturbances, depressed mood, craving, cognitive and attention deficits, and increased appetite.",
      "key": "b40225ff2e94efdcfeaf00d2c6d5717a",
      "line": 336,
      "relation": "increases",
      "source": 53,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "(-)-Nicotine withdrawal symptoms might begin within a few hours after the last nicotine product, and include irritability/anger/stress/anxiety, sleep disturbances, depressed mood, craving, cognitive and attention deficits, and increased appetite.",
      "key": "5516c0d9be8ede9e674373492ca54e50",
      "line": 337,
      "relation": "decreases",
      "source": 53,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "(-)-Nicotine withdrawal symptoms might begin within a few hours after the last nicotine product, and include irritability/anger/stress/anxiety, sleep disturbances, depressed mood, craving, cognitive and attention deficits, and increased appetite.",
      "key": "d11bb47a273a0f1f39cd063cbf32238a",
      "line": 338,
      "relation": "decreases",
      "source": 53,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "(-)-Nicotine withdrawal symptoms might begin within a few hours after the last nicotine product, and include irritability/anger/stress/anxiety, sleep disturbances, depressed mood, craving, cognitive and attention deficits, and increased appetite.",
      "key": "bc8bc3e7f3e101a69f4051e14e55a234",
      "line": 339,
      "relation": "increases",
      "source": 53,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "It is prescribed as medication for the treatment of depression (Wellbutrin®) and/or as an adjunct in smoking cessation therapy (Zyban®).",
      "key": "b6205557c069a2179de5a42c196517e3",
      "line": 366,
      "relation": "association",
      "source": 53,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Varenicline (Chantix®; Fig. 4) is prescribed as an adjunct medication in smoking cessation therapy and is thought to exert its effects as a partial agonist at α4β2 nAChRs and as a full agonist at α7 nAChRs [211, 212]. ",
      "key": "acd0dbd1103d9b75cde39a1002a4cd2d",
      "line": 381,
      "relation": "association",
      "source": 53,
      "target": 16
    },
    {
      "key": "16df25ca300f7eb5f1770192ed171ba1",
      "relation": "partOf",
      "source": 1,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Lobeline binds with high affinity to α4β2 nAChRs and displays mixed receptor agonist/antagonist actions (e.g., [150–154]).",
      "key": "fd085c0181b26e7671a00d4515b2249f",
      "line": 344,
      "relation": "increases",
      "source": 1,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Lobeline has, however, been shown to antagonize partially the stimulus effects of (-)-nicotine and S(+)-methamphetamine ([64, 160]; but see [66]).",
      "key": "c866037be47edd2056fcc87bf83ced2e",
      "line": 350,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 1,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Lobeline has, however, been shown to antagonize partially the stimulus effects of (-)-nicotine and S(+)-methamphetamine ([64, 160]; but see [66]).",
      "key": "87a8412d82cc436b22aa6ed6aa576bf4",
      "line": 351,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 1,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Bupropion [a.k.a. amfebutamone, (RS)-2-(tert-Butylamino)-1-(3-chlorophenyl)propan1-one, 3-Chloro tert-butylcathinone, 3-Chloro-N-tert-butyl-β-ketoamphetamine; Fig. 4] is a phenylaminoketone or cathinone derivative that is a weak central nervous system (CNS) stimulant",
      "key": "fa87c12b2e045adcd138324063e4f139",
      "line": 358,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 10,
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "It is prescribed as medication for the treatment of depression (Wellbutrin®) and/or as an adjunct in smoking cessation therapy (Zyban®).",
      "key": "ff27abb783f5048cbd641bb0de3a0fc1",
      "line": 365,
      "relation": "decreases",
      "source": 10,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "It is prescribed as medication for the treatment of depression (Wellbutrin®) and/or as an adjunct in smoking cessation therapy (Zyban®).",
      "key": "5c48d353ad28a44c28b459170b2634e6",
      "line": 366,
      "relation": "association",
      "source": 10,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Other studies have reported that bupropion blocked the acute effects of (-)-nicotine in a number of behavioral assays in mice (e.g., [171, 172])",
      "key": "95f2aba4ca8d6f16712a4b63097b7254",
      "line": 373,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 10,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Varenicline (Chantix®; Fig. 4) is prescribed as an adjunct medication in smoking cessation therapy and is thought to exert its effects as a partial agonist at α4β2 nAChRs and as a full agonist at α7 nAChRs [211, 212]. ",
      "key": "73879bcc3564601a88c2134c7c467298",
      "line": 381,
      "relation": "association",
      "source": 16,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Varenicline (Chantix®; Fig. 4) is prescribed as an adjunct medication in smoking cessation therapy and is thought to exert its effects as a partial agonist at α4β2 nAChRs and as a full agonist at α7 nAChRs [211, 212]. ",
      "key": "6bae622e8887dd56e4b03c322c460812",
      "line": 382,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 16,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Rosecrans JA",
          "Young R"
        ],
        "date": "2018-01-01",
        "db": "PubMed",
        "db_id": "28391535",
        "db_name": "Discriminative Stimulus Properties of S(-)-Nicotine: \"A Drug for All Seasons\".",
        "first": "Rosecrans JA",
        "journal": "Current topics in behavioral neurosciences",
        "last": "Young R",
        "pages": "51-94",
        "volume": "39"
      },
      "evidence": "Varenicline (Chantix®; Fig. 4) is prescribed as an adjunct medication in smoking cessation therapy and is thought to exert its effects as a partial agonist at α4β2 nAChRs and as a full agonist at α7 nAChRs [211, 212]. ",
      "key": "ee91ab0ab18fc7de7afc59a00aea21d1",
      "line": 383,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 16,
      "target": 24
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"(-)-cotinine\")",
      "concept": {
        "name": "(-)-cotinine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "f5fc7e0e2379ca3e6216c182d24ece00"
    },
    {
      "bel": "a(CHEBI:\"(-)-lobeline\")",
      "concept": {
        "name": "(-)-lobeline",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "9b027d23cef4e1cbefeaf9da1946c017"
    },
    {
      "bel": "a(CHEBI:\"(R)-nicotine\")",
      "concept": {
        "name": "(R)-nicotine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "9c866190b66aa41051279f1d2204c102"
    },
    {
      "bel": "a(CHEBI:\"(S)-anabasine\")",
      "concept": {
        "name": "(S)-anabasine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "cd74d70eeec2db316be0b94f8e410605"
    },
    {
      "bel": "a(CHEBI:\"(S)-nicotine\")",
      "concept": {
        "name": "(S)-nicotine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "53625fde103c51700bdfaab77f73a4b0"
    },
    {
      "bel": "a(CHEBI:\"insulin (human)\")",
      "concept": {
        "name": "insulin (human)",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "0df48c9be952fa6758da45684b16e731"
    },
    {
      "bel": "a(CHEBI:Anatabine)",
      "concept": {
        "name": "Anatabine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "9e5ab9569cca155e199162d8c20415b4"
    },
    {
      "bel": "a(CHEBI:Hexamethonium)",
      "concept": {
        "name": "Hexamethonium",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "4db95c29da75b3fbdcc274530e543143"
    },
    {
      "bel": "a(CHEBI:Mecamylamine)",
      "concept": {
        "name": "Mecamylamine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "0a541fa62f153d4c8ae539050da2562d"
    },
    {
      "bel": "a(CHEBI:adrenaline)",
      "concept": {
        "name": "adrenaline",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "0675be36381ca8fe2f73ea4595d7f925"
    },
    {
      "bel": "a(CHEBI:bupropion)",
      "concept": {
        "name": "bupropion",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "07a219e45e304acd5f11e8863e54247b"
    },
    {
      "bel": "a(CHEBI:dopamine)",
      "concept": {
        "name": "dopamine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "4c950dc480c64069e58998401b2083c1"
    },
    {
      "bel": "a(CHEBI:glucose)",
      "concept": {
        "name": "glucose",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "8b4d8974cf8c0e5830f78bb44168cf4d"
    },
    {
      "bel": "a(CHEBI:lactam)",
      "concept": {
        "name": "lactam",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "a73771ef8c3cd5211cf10bf6b56123a7"
    },
    {
      "bel": "a(CHEBI:nicotine)",
      "concept": {
        "name": "nicotine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "44ed555f78bacda2933ddef1d4280ce9"
    },
    {
      "bel": "a(CHEBI:nornicotine)",
      "concept": {
        "name": "nornicotine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "45a019f376f56f4dfcee8306c7845db9"
    },
    {
      "bel": "a(CHEBI:varenicline)",
      "concept": {
        "name": "varenicline",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "203e34366e86a604df08edbdf990ce4b"
    },
    {
      "bel": "a(HGNCGENEFAMILY:\"Cholinergic receptors nicotinic subunits\")",
      "concept": {
        "name": "Cholinergic receptors nicotinic subunits",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Abundance",
      "id": "a192e6f3df21a6ff54adc0af95fdff63"
    },
    {
      "bel": "a(MESH:\"Adrenal Glands\")",
      "concept": {
        "name": "Adrenal Glands",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "c91d55cb7894642ded4cba46ceef23d1"
    },
    {
      "bel": "a(MESH:\"Blood Glucose\")",
      "concept": {
        "name": "Blood Glucose",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "c598ab5b75268b0b9109c60541fc59ff"
    },
    {
      "bel": "a(MESH:\"Central Nervous System\")",
      "concept": {
        "name": "Central Nervous System",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "9480f2a1fd508f09840a01c1083e635e"
    },
    {
      "bel": "a(MESH:\"Dihydro-beta-Erythroidine\")",
      "concept": {
        "name": "Dihydro-beta-Erythroidine",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "e4aaa0f3f0c2020fb88e71c930967294"
    },
    {
      "bel": "a(MESH:\"Receptors, Nicotinic\")",
      "concept": {
        "name": "Receptors, Nicotinic",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "a06bdcddaf9cc29de921f81ce6f9b2e9"
    },
    {
      "bel": "a(MESH:\"Toxic Actions\")",
      "concept": {
        "name": "Toxic Actions",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "3f70d524d72b280eef1fafb12c44e1c2"
    },
    {
      "bel": "a(MESH:\"alpha7 Nicotinic Acetylcholine Receptor\")",
      "concept": {
        "name": "alpha7 Nicotinic Acetylcholine Receptor",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "58b5f9ca1e8fc58bac5d0b7c4002e2bd"
    },
    {
      "bel": "a(MESH:\"nicotinic receptor alpha3beta2\")",
      "concept": {
        "name": "nicotinic receptor alpha3beta2",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "a9483d79f2ac705a295314d0681b9d7d"
    },
    {
      "bel": "a(MESH:\"nicotinic receptor alpha3beta4\")",
      "concept": {
        "name": "nicotinic receptor alpha3beta4",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "3f639b3a4a9177da87f05730553f4849"
    },
    {
      "bel": "a(MESH:\"nicotinic receptor alpha4beta2\")",
      "concept": {
        "name": "nicotinic receptor alpha4beta2",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "a896a5b33bbe3a8801a7622bc4a82c98"
    },
    {
      "bel": "a(MESH:Liver)",
      "concept": {
        "name": "Liver",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "e30cfc38f11ab042209eb4fc62bc6a02"
    },
    {
      "bel": "a(MESH:Lung)",
      "concept": {
        "name": "Lung",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "01153b8afebc21b98ee3c9ceb2b46df9"
    },
    {
      "bel": "a(MESH:Tobacco)",
      "concept": {
        "name": "Tobacco",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "95a6aa669edf3e2d116b1e43e56a8eeb"
    },
    {
      "bel": "a(PUBCHEM:4032)",
      "concept": {
        "name": "4032",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "224f40bf846307c58643948bcc8ba408"
    },
    {
      "bel": "a(PUBCHEM:5288811)",
      "concept": {
        "name": "5288811",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "7ca205ff51400232a317077eb51dfd31"
    },
    {
      "bel": "a(PUBCHEM:9306)",
      "concept": {
        "name": "9306",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "d146d09053757435ab8610d78638cc56"
    },
    {
      "bel": "bp(GO:\"cellular respiration\")",
      "concept": {
        "name": "cellular respiration",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "ced509226a10b89fb0f158c6a90c60c2"
    },
    {
      "bel": "bp(GO:\"nicotine metabolic process\")",
      "concept": {
        "name": "nicotine metabolic process",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "d1e40c1ed199249e598728c904640abd"
    },
    {
      "bel": "bp(GO:cognition)",
      "concept": {
        "name": "cognition",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "24220ec2073c35bcd945681ee9c6ea38"
    },
    {
      "bel": "bp(MESH:\"Heart Rate\")",
      "concept": {
        "name": "Heart Rate",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "04c7567a808ed8cd352b78e95310d948"
    },
    {
      "bel": "complex(a(CHEBI:\"(-)-lobeline\"), a(MESH:\"nicotinic receptor alpha4beta2\"))",
      "function": "Complex",
      "id": "e5aa4f80eb370189613eec24cce493cb",
      "members": [
        {
          "bel": "a(CHEBI:\"(-)-lobeline\")",
          "concept": {
            "name": "(-)-lobeline",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "9b027d23cef4e1cbefeaf9da1946c017"
        },
        {
          "bel": "a(MESH:\"nicotinic receptor alpha4beta2\")",
          "concept": {
            "name": "nicotinic receptor alpha4beta2",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "a896a5b33bbe3a8801a7622bc4a82c98"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:nicotine), a(HGNCGENEFAMILY:\"Cholinergic receptors nicotinic subunits\"))",
      "function": "Complex",
      "id": "7515692e7617cecafe6ecbbab6912f69",
      "members": [
        {
          "bel": "a(CHEBI:nicotine)",
          "concept": {
            "name": "nicotine",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "44ed555f78bacda2933ddef1d4280ce9"
        },
        {
          "bel": "a(HGNCGENEFAMILY:\"Cholinergic receptors nicotinic subunits\")",
          "concept": {
            "name": "Cholinergic receptors nicotinic subunits",
            "namespace": "HGNCGENEFAMILY"
          },
          "function": "Abundance",
          "id": "a192e6f3df21a6ff54adc0af95fdff63"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:nicotine), a(MESH:\"nicotinic receptor alpha4beta2\"))",
      "function": "Complex",
      "id": "ecc6d8354ea7ff3e332545f530290df0",
      "members": [
        {
          "bel": "a(CHEBI:nicotine)",
          "concept": {
            "name": "nicotine",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "44ed555f78bacda2933ddef1d4280ce9"
        },
        {
          "bel": "a(MESH:\"nicotinic receptor alpha4beta2\")",
          "concept": {
            "name": "nicotinic receptor alpha4beta2",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "a896a5b33bbe3a8801a7622bc4a82c98"
        }
      ]
    },
    {
      "bel": "complex(a(MESH:\"Dihydro-beta-Erythroidine\"), a(MESH:\"nicotinic receptor alpha4beta2\"))",
      "function": "Complex",
      "id": "6edaf68f8e061b697dc2c5d546281664",
      "members": [
        {
          "bel": "a(MESH:\"Dihydro-beta-Erythroidine\")",
          "concept": {
            "name": "Dihydro-beta-Erythroidine",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "e4aaa0f3f0c2020fb88e71c930967294"
        },
        {
          "bel": "a(MESH:\"nicotinic receptor alpha4beta2\")",
          "concept": {
            "name": "nicotinic receptor alpha4beta2",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "a896a5b33bbe3a8801a7622bc4a82c98"
        }
      ]
    },
    {
      "bel": "complex(a(MESH:\"Dihydro-beta-Erythroidine\"), p(HGNC:CHRNB2))",
      "function": "Complex",
      "id": "d53b1a03744a7a5f0fd033d25dd0e6ba",
      "members": [
        {
          "bel": "a(MESH:\"Dihydro-beta-Erythroidine\")",
          "concept": {
            "name": "Dihydro-beta-Erythroidine",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "e4aaa0f3f0c2020fb88e71c930967294"
        },
        {
          "bel": "p(HGNC:CHRNB2)",
          "concept": {
            "name": "CHRNB2",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7e5d65d97e555667e0928696d86663e6"
        }
      ]
    },
    {
      "bel": "complex(p(GO:\"I-kappaB/NF-kappaB complex\"))",
      "function": "Complex",
      "id": "d32de53c2beff68d985e4d85c1600e7b",
      "members": [
        {
          "bel": "p(GO:\"I-kappaB/NF-kappaB complex\")",
          "concept": {
            "name": "I-kappaB/NF-kappaB complex",
            "namespace": "GO"
          },
          "function": "Protein",
          "id": "b52b99cbd49bc52ac106dec4eb636ecd"
        }
      ]
    },
    {
      "bel": "p(GO:\"I-kappaB/NF-kappaB complex\")",
      "concept": {
        "name": "I-kappaB/NF-kappaB complex",
        "namespace": "GO"
      },
      "function": "Protein",
      "id": "b52b99cbd49bc52ac106dec4eb636ecd"
    },
    {
      "bel": "p(HGNC:CHRNB2)",
      "concept": {
        "name": "CHRNB2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7e5d65d97e555667e0928696d86663e6"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Cholinergic receptors nicotinic subunits\")",
      "concept": {
        "name": "Cholinergic receptors nicotinic subunits",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "8038209bc0b5bd919a7208d644f913f8"
    },
    {
      "bel": "path(MESH:\"Behavior, Addictive\")",
      "concept": {
        "name": "Behavior, Addictive",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "591ce7dffbbd2b437e2cca6c2e68a202"
    },
    {
      "bel": "path(MESH:\"Bipolar Disorder\")",
      "concept": {
        "name": "Bipolar Disorder",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "5e400b2946cf4f0d4eceb7d7bf8c2a0e"
    },
    {
      "bel": "path(MESH:\"Blood Pressure\")",
      "concept": {
        "name": "Blood Pressure",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "4abd0c9cfb634a6105a4d64cc5e27ed0"
    },
    {
      "bel": "path(MESH:\"Irritable Mood\")",
      "concept": {
        "name": "Irritable Mood",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "8d5a198fdb9c3be6187e936b4aec0351"
    },
    {
      "bel": "path(MESH:\"Motor Activity\")",
      "concept": {
        "name": "Motor Activity",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "f382cf35005457ced840abe2c7476ee9"
    },
    {
      "bel": "path(MESH:\"Sleep Wake Disorders\")",
      "concept": {
        "name": "Sleep Wake Disorders",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "bfc01f795624b5c78965e77b95dd72f9"
    },
    {
      "bel": "path(MESH:\"Smoking Cessation\")",
      "concept": {
        "name": "Smoking Cessation",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "83300dbb97f30192954088acd6e06bb1"
    },
    {
      "bel": "path(MESH:\"Stress, Psychological\")",
      "concept": {
        "name": "Stress, Psychological",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "0fd6cd2d5509c71efc2fae204e14e188"
    },
    {
      "bel": "path(MESH:Anger)",
      "concept": {
        "name": "Anger",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "3cb56331df51ea722b7f9973d2f70f22"
    },
    {
      "bel": "path(MESH:Anxiety)",
      "concept": {
        "name": "Anxiety",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "81296be1c4ea6bcc3d464a0a9d9342b0"
    },
    {
      "bel": "path(MESH:Appetite)",
      "concept": {
        "name": "Appetite",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "1d7640f79a070afa040ff5b9dfb2a9c4"
    },
    {
      "bel": "path(MESH:Attention)",
      "concept": {
        "name": "Attention",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "f22e7196f5d0614ad79325e3690466ec"
    },
    {
      "bel": "path(MESH:Confusion)",
      "concept": {
        "name": "Confusion",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "415f15fabd2d2a6ea9c541e58be7aa37"
    },
    {
      "bel": "path(MESH:Craving)",
      "concept": {
        "name": "Craving",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "a3602eff36e29d05ad327cceae447401"
    },
    {
      "bel": "path(MESH:Death)",
      "concept": {
        "name": "Death",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "10a8517e414b47762b224fc2cc999027"
    },
    {
      "bel": "path(MESH:Depression)",
      "concept": {
        "name": "Depression",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "4cbb9f9f3c1f12c3f20dc0eb627a8224"
    },
    {
      "bel": "path(MESH:Hypertension)",
      "concept": {
        "name": "Hypertension",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "dfc5303e42570a3507bbb51f1a445664"
    },
    {
      "bel": "path(MESH:Motivation)",
      "concept": {
        "name": "Motivation",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "f416b88d349a22135f63411787110178"
    },
    {
      "bel": "path(MESH:Pleasure)",
      "concept": {
        "name": "Pleasure",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "ecf355fb0a22c6a303937b51d238a95d"
    },
    {
      "bel": "path(MESH:Seizures)",
      "concept": {
        "name": "Seizures",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "70d77d326911c2a2fc35d764b4963e57"
    },
    {
      "bel": "path(MESH:Smoking)",
      "concept": {
        "name": "Smoking",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "421977e25516b65692cc5c7ed794a7eb"
    },
    {
      "bel": "path(MESH:Tremor)",
      "concept": {
        "name": "Tremor",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "b041fa5b6e0d8f3cda2244378dd215f7"
    }
  ]
}